Thursday - July 10, 2025
NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading provider of virtual primary care services, today announced the launch of new membership plans that enable immediate access to best-in-class virtual care. LifeMD’s new plans, powered by innovative features and enhancements to its proprietary app, expand care and provide patients with the most flexibility when seeking virtual treatment.
Effective immediately, all consumers can download LifeMD’s free mobile app to gain access to its proprietary symptom checker, use its discounted prescription card and access its provider network for virtual appointments in seconds. In addition, LifeMD now offers a live appointment queue where patients can seek and receive a virtual appointment immediately, providing a best-in-class ability that addresses urgent care needs that benefit from prompt medical guidance and attention.
“As a physician, I know first-hand the importance of real-time access to a doctor, as well as the impact that the doctor-patient relationship can have on driving positive health outcomes,” said Anthony Puopolo, MD, Chief Medical Officer, LifeMD. “Our new features, including immediate queue appointments, enable patients to improve their overall health with convenient, quick access to trusted providers who can deliver exceptional care for the entire family.”
LifeMD’s new membership tiers provide flexibility for patients looking for high-quality care with or without health insurance, and are as follows:
“Whether a patient is looking for a one-time doctor visit or more comprehensive, ongoing care and coverage, our new care plans give patients choice and flexibility,” said Jessica Friedeman, Chief Marketing Officer, LifeMD. “With this launch, LifeMD is advancing a new paradigm of care – one where patients can now receive treatment from a highly rated provider within minutes and access exclusive programs such as comprehensive weight management treatment with GLP-1 medications and nutritional support.”
According to Bain and Co., by 2030 one-third of the $300B per year primary care market is expected to be disrupted by non-traditional and virtual primary providers like LifeMD. LifeMD’s highly flexible virtual primary care platform supports direct-to-consumer offerings across preventative care and wellness, urgent care, and chronic care management, as well as the needs of healthcare product companies, payers, and employers seeking cost-effective virtual care solutions that facilitate access to outcome-oriented care. The company’s release of innovative features and expansion of clinical capabilities is expected to facilitate continued membership growth and demonstrates its distinct presence in the evolving telehealth landscape.
About LifeMD
LifeMD is a leading provider of virtual primary care. The company offers telemedicine, laboratory and pharmacy services, and specialized treatment across more than 200 conditions including primary care, men’s health, women’s health, allergy & asthma, and dermatology. Leveraging a vertically integrated proprietary digital care platform, 50-state affiliated medical group, and US-based patient care center, LifeMD is simplifying healthcare, increasing access to top-notch, affordable, and patient-centric care. For more information, please visit LifeMD.com.
Media Contact
press@lifemd.com
Investor Contact
Marc Benathen, CFO
marc@lifemd.com
Last Trade: | US$11.78 |
Daily Change: | -0.19 -1.59 |
Daily Volume: | 1,100,343 |
Market Cap: | US$535.400M |
May 22, 2025 April 28, 2025 March 10, 2025 March 06, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load